HALO Halozyme Therapeutics Inc.

Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Halozyme Therapeutics Inc. market cap is $7.16B.

52 week high is the highest price of a stock in the past 52 weeks, or one year. Halozyme Therapeutics Inc. 52 week high is $57.09 as of July 27, 2024.

52 week low is the lowest price of a stock in the past 52 weeks, or one year. Halozyme Therapeutics Inc. 52 week low is $32.83 as of July 27, 2024.

Halozyme Therapeutics Inc. stock price today is $56.23.

Halozyme Therapeutics Inc. stock price yesterday was $55.97.

The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Halozyme Therapeutics Inc.’s P/E ratio is 23.26.

The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Halozyme Therapeutics Inc. P/B ratio is 40.2212.

EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Halozyme Therapeutics Inc.'s EBITDA is 13.61.

The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Halozyme Therapeutics Inc. 50-day moving average is $50.04.

Halozyme Therapeutics Inc. has 373 employees.